Institute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Medical Clinic III, Pulmonology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Histol Histopathol. 2024 Apr;39(4):437-446. doi: 10.14670/HH-18-647. Epub 2023 Jun 26.
Despite promising results of targeted therapy approaches, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death. Tripartite motif containing 11 (TRIM11) is part of the TRIM family of proteins, playing crucial roles in tumor progression. TRIM11 serves as an oncogene in various cancer types and has been reported to be associated with a poor prognosis. In this study, we aimed to investigate the protein expression of TRIM11 in a large NSCLC cohort and to correlate its expression with comprehensive clinico-pathological data.
Immunohistochemical staining of TRIM11 was performed on a European cohort of NSCLC patients (n=275) including 224 adenocarcinomas and 51 squamous cell carcinomas. Protein expression was categorized according to staining intensity as absent, low, moderate and high. To dichotomize samples, absent and low expression was defined as weak and moderate and high expression was defined as high. Results were correlated with clinico-pathological data.
TRIM11 was significantly more highly expressed in NSCLC than in normal lung tissue and significantly more highly expressed in squamous cell carcinomas than in adenocarcinomas. We found a significantly worse 5-year overall survival for patients who highly expressed TRIM11 in NSCLC.
High TRIM11 expression is linked with a poor prognosis and might serve as a promising novel prognostic biomarker for NSCLC. Its assessment could be implemented in future routine diagnostic workup.
尽管靶向治疗方法取得了可喜的成果，但非小细胞肺癌（NSCLC）仍然是癌症相关死亡的主要原因。三结构域包含蛋白 11（TRIM11）是 TRIM 蛋白家族的一部分，在肿瘤进展中发挥着关键作用。TRIM11 在多种癌症类型中是一种癌基因，并且与预后不良有关。在本研究中，我们旨在研究大量 NSCLC 患者队列中 TRIM11 的蛋白表达，并将其表达与全面的临床病理数据相关联。
对包括 224 例腺癌和 51 例鳞状细胞癌在内的欧洲 NSCLC 患者队列（n=275）进行了 TRIM11 的免疫组织化学染色。根据染色强度将蛋白表达分为缺失、低、中和高。为了将样本二分类，缺失和低表达定义为弱，中到高表达定义为高。结果与临床病理数据相关联。
TRIM11 在 NSCLC 中明显高于正常肺组织，在鳞状细胞癌中明显高于腺癌。我们发现，在 NSCLC 中高表达 TRIM11 的患者 5 年总生存率明显降低。
高 TRIM11 表达与预后不良有关，可能成为 NSCLC 有前途的新型预后生物标志物。其评估可以在未来的常规诊断工作中实施。
